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The feline immunodeficiency virus (FIV) targets activated CD4-positive helper T cells preferentially, induc-
ing an AIDS-like immunodeficiency in its natural host species, the domestic cat. The primary receptor for FIV
is CD134, a member of the tumor necrosis factor receptor superfamily, and all primary viral strains tested to
date use CD134 for infection. We examined the expression of CD134 in the cat using a novel anti-feline CD134
monoclonal antibody (MAb), 7D6, and showed that as in rats and humans, CD134 expression is restricted
tightly to CD4, and not CD8, T cells, consistent with the selective targeting of these cells by FIV. However,
FIV is also macrophage tropic, and in chronic infection the viral tropism broadens to include B cells and CD8
T cells. Using 7D6, we revealed CD134 expression on a B220-positive (B-cell) population and on cultured
macrophages but not peripheral blood monocytes. Moreover, macrophage CD134 expression and FIV infection
were enhanced by activation in response to bacterial lipopolysaccharide. Consistent with CD134 expression on
human and murine T cells, feline CD134 was abundant on mitogen-stimulated CD4 T cells, with weaker
expression on CD8 T cells, concordant with the expansion of FIV into CD8 T cells with progression of the
infection. The interaction between FIV and CD134 was probed using MAb 7D6 and soluble CD134 ligand
(CD134L), revealing strain-specific differences in sensitivity to both 7D6 and CD134L. Infection with isolates
such as PPR and B2542 was inhibited well by both 7D6 and CD134L, suggesting a lower affinity of interaction.
In contrast, GL8, CPG, and NCSU were relatively refractory to inhibition by both 7D6 and CD134L and,
accordingly, may have a higher-affinity interaction with CD134, permitting infection of cells where CD134 levels
are limiting.
The initial event in the process of viral entry into a target cell
is the interaction between the virus and its cellular receptor,
and the specificity of this interaction determines both the cell
tropism and the pathogenicity of the virus. The primary recep-
tor for the feline immunodeficiency virus (FIV) is CD134
(OX40), a member of the tumor necrosis factor receptor
(TNFR) superfamily. Ectopic expression of feline CD134 in
nonpermissive cells renders the cells permissive for binding of
both virus (29) and soluble envelope glycoprotein (Env) (12).
CD134 expression alone is insufficient to confer susceptibility
to infection with FIV; infection requires the expression of a
coreceptor which for FIV is the chemokine receptor CXCR4
(CD184) (37, 40). In the presence of the CXCR4 antagonist
AMD3100, CD134-dependent infection is ablated. Further,
the interaction between FIV and CD134 is species specific;
human CD134 does not support FIV infection (29) and, thus,
FIV is not xenotropic for human cells. The species specificity of
the FIV-CD134 interaction has facilitated the mapping of the
determinants on CD134 that mediate both the binding of sol-
uble Env and viral entry. Using chimeric molecules generated
by exchanging fragments of feline and human CD134, the
binding site for soluble (dimeric) Env was mapped to the first
cysteine-rich domain (CRD1) of CD134 (11); however, al-
though expression of the feline CRD1 in the context of human
CD134 rendered cells permissive for infection with the PPR
strain of FIV, additional determinants in the second CRD
(CRD2) are essential for infection with primary strains, such as
GL8 (39). CRD2 contributes to the CD134 ligand (CD134L)
binding site on feline CD134 (38), indicating that FIV infection
may be sensitive to modulation by CD134L (OX40L, CD252).
Previous analyses of CD134 expression on feline cells have
relied on a cross-species-reactive anti-human CD134 monoclo-
nal antibody (MAb) and have yielded inconsistent data (11, 21,
29). Observations regarding CD134-dependent targeting of
FIV have relied on inferred data from binding experiments
with recombinant dimeric envelope glycoprotein immunoglob-
ulin G (IgG)-Fc fusion protein (SU-Fc) and subsequent im-
munoblotting and could not examine surface expression of
CD134 due to the absence of reagents with sufficient specificity
and sensitivity (12). Similarly, the effect of CD134L on FIV
infection has not been assessed rigorously, as a feline CD134
binding ligand was not available. The effect of CD134L on FIV
infection was inferred from binding studies using human
* Corresponding author. Mailing address: Retrovirus Research Lab-
oratory, Institute of Comparative Medicine, Faculty of Veterinary
Medicine, University of Glasgow, Bearsden Road, Glasgow G61 1QH,
United Kingdom. Phone: 44 141 330 3274. Fax: 44 141 330 2271.
E-mail: b.willett@vet.gla.ac.uk.
 Published ahead of print on 3 July 2007.
9665
 at BIBLIO
THEQUE DU CHUV on July 15, 2008 
jvi.asm.org
D
ow
nloaded from
 
CD134L and chimeric CD134 molecules bearing CRD1 of
feline CD134 in the context of human CD134 (11). Bearing in
mind this caveat, the binding site for dimeric SU-Fc was
mapped to CRD1 of CD134, while the binding site for human
CD134L appeared to be formed by CRDs 2 and 3 (11). The
failure of human CD134L to block binding of dimeric FIV
SU-Fc to cells expressing a chimeric feline CRD1 in the con-
text of human CD134 was interpreted as suggesting that FIV
infection would not be modulated by native feline CD134L
(11). Subsequent structural analyses of the human and murine
CD134-CD134L interaction have revealed that the receptor
and ligand make multiple contacts using regions from all three
CRDs of CD134 (7), including CRD1, the region bearing the
predicted FIV Env binding site. Moreover, recent studies have
demonstrated that many primary strains of FIV require a com-
plex determinant on CD134 that requires determinants in
CRD2, indicating a possible overlap with the CD134L binding
site (38, 39) and the potential for modulation of FIV infection
by CD134L. In this study we evaluated the role of CD134 and
CD134L in FIV infection. To facilitate our analyses we gener-
ated a novel monoclonal antibody recognizing feline CD134
with a high affinity and we cloned the feline CD134L homo-
logue. Using these reagents, we analyzed the expression of
CD134 in the domestic cat and we show that FIV infection is
modulated by both antibody and ligand binding.
MATERIALS AND METHODS
Cells and viruses. MYA-1 (23), MCC (6), CLL (39), and NSO cell lines were
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2
mM glutamine, 0.11 mg/ml sodium pyruvate, 100 IU/ml penicillin, and 100 g/ml
streptomycin (complete RPMI). 293T and NP2 cells were maintained in Dul-
becco’s modification of Eagle’s medium supplemented as above. The medium for
MYA-1 cells was supplemented with conditioned medium from a murine cell line
(L2.3) transfected with a human interleukin-2 (IL-2) expression construct (equiv-
alent to 100 U/ml of recombinant human IL-2) and 50 M 2-mercaptoethanol.
All media and supplements were obtained from InVitrogen Life Technologies
Ltd. (Paisley, United Kingdom). Stable cell lines expressing constructs based on
the pDONAI (Takara) or PCR3 (InVitrogen) expression vectors were main-
tained in G418-supplemented medium (InVitrogen, Paisley, United Kingdom),
while those based on pTorsten (31) were maintained in hygromycin-supple-
mented medium. Splenic macrophages were isolated from spleen tissue collected
post mortem. Cells were separated from tissue by teasing with crossed scalpels,
washed by centrifugation, and plated overnight at 37°C. Nonadherent cells were
removed by pipetting, while adherent cells were cultured in complete RMI
supplemented with supernatant from Chinese hamster ovary (CHO) cells stably
transfected with feline granulocyte-macrophage colony-stimulating factor (GM-
CSF; kindly provided by S. Dunham). Lipopolysaccharide (LPS) stimulation
experiments used LPS from Escherichia coli 0127:B8 (Sigma, Poole, United
Kingdom).
Antibodies and flow cytometry. Fluorescein isothiocyanate (FITC)-conjugated
anti-feline CD4 (VPG34), R-phycoerythrin (PE)-conjugated anti-feline CD8
(VPG9), and anti-human CD14 (Tuk4)–FITC conjugate were obtained from
AbD Serotec (Oxford, United Kingdom). Anti-human CD134 (BerACT35) was
obtained from Alexis Biochemicals (Axxora Ltd., Nottingham, United King-
dom). Anti-mouse B220 (CD45R) was from BD Biosciences (Pharmingen, Ox-
ford, United Kingdom). Anti-human CXCR4 (no. 44701) was obtained from
R&D Systems, Abingdon, Oxford, United Kingdom. Cells to be processed for
flow cytometry were resuspended in phosphate-buffered saline (PBS) supple-
mented with 1.0% (wt/vol) bovine serum albumin, 0.1% (wt/vol) sodium azide
(PBA). Cells were incubated with 1 g of primary antibody for 30 min at 4°C and
then washed twice with PBA by centrifugation at 1,000 rpm for 5 min. Bound
primary antibody was detected with the appropriate anti-mouse IgG secondary
antibody (AbD Serotec) corresponding to the isotype of the primary antibody
and conjugated to either FITC or PE. Cells were incubated with secondary
antibody for 30 min at 4°C and then washed twice with PBA by centrifugation at
1,000 rpm for 5 min and resuspended in 1 ml of PBA for analysis. All samples
were analyzed on a Beckman Coulter EPICS MCS-XL flow cytometer, 10,000
events being collected for each sample in LIST mode. Data were analyzed using
EXPO 32 ADC Analysis (Advanced Cytometry Systems).
Production of anti-feline CD134 monoclonal antibody. Feline CD134 cDNA
(29) was amplified from pDONAI.fCD134 using the oligonucleotides 5-CGAT
CTAGAATGAGGGTGGTTGTGGGGGCT-3 and 5-ATGGGATCCCGCT
GGGGACCCCTGGGGGGCTC-3 and the Expand high-fidelity PCR system
and cloned as an XbaI/BamHI fragment into the pTorsten expression vector
(30). CHO cells were then transfected with the pTorsten.fCD134-Fc construct
using Superfect (QIAGEN Ltd., Crawley, United Kingdom) and selected in
hygromycin (Sigma, Poole, United Kingdom). CD134–IgG-Fc was then purified
by affinity chromatography using protein A-Sepharose (HiTrap Protein A HP;
GE Healthcare, Chalfont St. Giles, United Kingdom) and bound protein eluted
with 0.1 M glycine pH 3.0, neutralizing the eluate immediately to pH 7.0 by
collection into 1.5 M Tris pH 8.6. The integrity of the purified protein was
assessed by immunoblotting, and the fusion protein was detected with goat
anti-human IgG-Fc horseradish peroxidase conjugate (Sigma, Poole, Dorset,
United Kingdom) and visualized with amino-9-ethylcarbazole (Vectastain AEC
substrate kit; Vector Laboratories Ltd., Peterborough, United Kingdom).
BALB/c mice received one immunization of 25 g CD134–IgG-Fc protein in
complete Freund’s adjuvant followed by two further immunizations at monthly
intervals with 25 g protein in incomplete Freund’s adjuvant. Prebleed samples
were analyzed for anti-CD134 reactivity by enzyme-linked immunosorbent assay
(ELISA) prior to a final single immunization 1 week in advance of splenectomy.
Lymphocytes were isolated from spleens by centrifugation over Ficoll (GE
Healthcare), washed, and fused with NSO myeloma cells. Cells were then plated
in complete RPMI supplemented with 100 M hypoxanthine, 0.4 M aminop-
terin, and 16 M thymidine (HAT medium supplement Hybri-Max; Sigma).
Approximately 2 weeks postplating, supernatants from 1,008 wells were screened
by ELISA for anti-CD134-Fc reactivity. A 0.25-g aliquot from each well of
CD134-Fc was bound overnight to 96-well high-binding ELISA assay plates
(Greiner Bio-One) in coating buffer (0.05 M carbonate-bicarbonate, pH 9.6) at
room temperature. Plates were then washed and blocked with 1.0% skimmed
milk (Marvel) in phosphate-buffered saline containing 0.1% Tween 20 (PBS-
Tween). Wells were then incubated with hybridoma culture supernatants for 1 h,
washed in PBS-Tween, and then incubated for a further hour with sheep anti-
mouse IgG–horseradish peroxidase conjugate (Sigma) in 1.0% skimmed milk–
PBS-Tween. Wells were washed once again with PBS-Tween, and then 3,3,5,5-
tetramethylbenzidine substrate (Sigma) was added and incubated for 30 min, at
which time the absorbance at 450 nm was recorded using a Microscan Ascent
plate reader (Thermo Life Sciences). Supernatants from 129 hybridoma wells
containing anti-CD134 activity were screened by flow cytometry against CLL-
fCD134 cells (38), identifying seven supernatants with activity against native
CD134 on mammalian cells. Of these seven hybridomas, a single hybridoma
(7D6) proved stable and had a reactivity that was confirmed as specific for
CD134; this hybridoma was cloned and expanded. Culture supernatants were
pooled and filtered at 0.45 m, and the monoclonal antibody was affinity purified
on protein A-Sepharose, eluted with 0.1 M sodium citrate pH 3.0, and neutral-
ized with 1.5 M Tris buffer pH 8.6.
Reactivity of the MAb was confirmed by flow cytometry and immunoblotting.
In the latter case, bound MAb was detected using biotinylated horse anti-mouse
IgG (Vector Laboratories Ltd.) followed by development with VECTASTAIN
ABC-AmP reagent and 5-bromo-4-chloro-3-indolyl phosphate–nitroblue tetra-
zolium substrate.
Molecular cloning of feline CD134L. The 2X cat genome database (http://www
.ncbi.nlm.nih.gov/genome/guide/cat/) was searched using the NCBI gene symbol
TNFSF4. The genomic fragments identified were then aligned with published
murine and human CD134L sequences (U12763 and X79929, respectively) and
used to identify the 5 and 3 regions of the orthologous feline CD134L coding
sequence from which oligonucleotide primers could be designed based on re-
gions of consensus sequence. Total RNA was prepared from MCC and MYA-1
cells using RNAqueous (Ambion, Applied Biosystems, Warrington, United
Kingdom), and first-strand cDNA was synthesized using oligo(dT) primer and
RETROscript (Ambion) as per the manufacturer’s instructions. Feline CD134L
cDNA was then amplified by PCR from total cDNA, using the primers 5-GAA
GAT GGA AGG GGT CCA ACC CCT GGA TGA-3 and 5-CTC AAA GGA
CAC AGA A(G/T)C CAC CAG GAT TTT-3 and Roche Expand high-fidelity
PCR reagent (Roche) on a Perkin-Elmer 9700 thermal cycler. Products were
then cloned into the pCR-TOPO vector (TOPO TA cloning kit; InVitrogen) and
their nucleic acid sequence determined by cycle sequencing on an Applied
Biosystems 9700 thermal cycler using a BigDye Terminator v1.1 cycle sequencing
kit (Applied Biosystems) followed by analysis on an Applied Biosystems 3700
genetic analyzer. For ectopic expression of native feline CD134L (fCD134L) in
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feline cells, the fCD134L cDNA was subcloned into pDONAI retroviral vector
(Takara) and packaged into murine leukemia virus particles by cotransfection
into HEK 293T cells with pHIT60 and PCI-VSV-G as previously described (35).
Viral pseudotypes were then used to transduce MCC cells before selection 72 h
posttransduction in G418-supplemented medium.
Preparation of HIV (FIV) pseudotypes. FIV env gene expression constructs
GL8, B2542, CPG41, and 0827 have been described previously (29, 38, 39). Five
g of each VR1012-env and 7.5 g of pNL4-3-Luc-ER were cotransfected
into HEK 293T cells by using the calcium-phosphate coprecipitation technique
essentially as described previously (19). Culture supernatants were collected at
48 h posttransfection, filtered at 0.45 m, and frozen at 80°C until required.
Adherent target cell lines were seeded at 1  104 cells per well of a Cultur-
Plate-96 assay plate (Perkin-Elmer, Life and Analytical Sciences, Beaconsfield,
United Kingdom) and cultured overnight, while suspension target cell lines were
seeded at 5  104 cells per well and used immediately. The cells were then
infected with 50 l of human immunodeficiency virus (HIV) (FIV) luciferase
pseudotypes and cultured for 72 h, and then luciferase activity was quantified by
the addition of 50 l of Steadylite HTS (Perkin-Elmer) luciferase substrate and
measurement by single-photon counting on a MicroBeta TriLux luminometer
(Perkin-Elmer).
Inhibition of viral entry. A total of 5 104 MCC-fCD134 or MYA-1 cells were
incubated with increasing concentrations of purified 7D6 monoclonal antibody
or CD134L in complete medium for 30 min at room temperature. Viral
pseudotypes were added, incubated for a further hour, and then washed once by
centrifugation. Cells were then plated in 96-well culture-treated luciferase assay
plates (CulturPlate 96) in complete medium in the presence of maintenance
antibody or ligand at a 1:3 dilution of the blocking concentration. Cultures were
maintained for 72 h postinfection, at which point glow luciferase assay substrate
was added and luminescence quantified.
Production of recombinant IgG-Fc fusion proteins. Fc-murine CD134L
(mCD134L) was produced from Fc-mCD134L-expressing 293 cells in CELLine
AD1000 bioreactor flasks (Integra Biosciences [Scientific Laboratory Supplies,
Nottingham, United Kingdom]) in medium supplemented with low-IgG serum
(Integra Biosciences). Culture supernatant was filtered at 0.22 m and frozen at
80°C prior to use in order to preserve optimal bioactivity. Protein concentra-
tion was estimated by immunoblotting using protein A-purified Fc-mCD134L of
known concentration as a standard. Fc-mCD134L and Fc-hCD134L were also
expressed from vectors described previously (pPS1763 and PS1466) (5). The
extracellular domain of feline CD134L was subcloned as a PstI/EcoRI fragment
into the same vector (pPS1297) (20). For this purpose, fCD134L cDNA was
amplified using primers 5-GCTGCAGGTGCCACCTCAGTATCCTCCAATT-3
and 5-CGAATTCTCAAAGGACACAGCCACCAGG-3. FIV Env SU-Fc fu-
sion proteins were produced by amplifying the SU coding sequence with the
oligonucleotide primers 5-CGATCTAGAAACAATAATTATGGCAGAAG-3
FIG. 1. Characterization of anti-feline CD134 MAb 7D6. MCC cells expressing feline CD134 (B and E), human CD134 (C and F), or vector
only (A and D) were stained with 7D6 (A to C) or BerACT35 (D to F). MYA-1 cells (G and H) were stained with 7D6 (G) or BerACT35 (H).
Primary antibodies were detected with phycoerythrin-conjugated anti-mouse IgG. Cells were processed for flow cytometry, and 10,000 events were
collected in LIST mode. (I) Reactivity of 7D6 in an immunoblot assay. Affinity-purified soluble feline CD134-Fc (lane 1) or lysates from MCC
vector-only control (lane 2) or CD134-transduced cells (lane 3) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
followed by immunoblotting with 7D6 MAb (endogenous; full-length CD134 is indicated by the arrow, lane 3).
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and 5-GGCGGCCGCTGGTACCAC(C/T)AAGTAATC-3 corresponding to
the start codon for the Env leader sequence and the SU/TM junction, respec-
tively. The amplified products were cloned as XbaI/NotI fragments into pTorsten
(30), expressed in CHO cells, and purified as above.
Binding of FIV SU-Fc to CD134. MCC cells expressing feline CD134
were incubated with increasing concentrations of monoclonal antibodies 7D6,
BerACT35 (Santa Cruz Biotechnology, Santa Cruz, CA), or anti-feline CD8
(VPG9; AbD Serotec) for 30 min at room temperature in complete RPMI
supplemented with 10 mM N-(2-hydroxyethyl) piperazine-N-(2-ethanesul-
fonic acid). A 0.5-g aliquot of SU Fc fusion protein was added and incu-
bated for a further 30 min at room temperature. Cells were then washed twice
by centrifugation through PBA at 1,000 rpm and incubated with PE-conju-
gated anti-human IgG-Fc (eBioscience, San Diego, CA) for 30 min at 4°C.
Cells were then washed twice with PBA by centrifugation at 1,000 rpm for 5
min and resuspended in 1 ml of PBA for analysis and analyzed by flow
cytometry as above.
FIG. 2. Detection of CD134 on IL2-dependent T cells using BerACT35. MYA-1 or Q201 T cells were stained for CD134 using anti-feline
CD134 MAb 7D6 or the cross-species-reactive anti-human CD134 MAb BerACT35. Bound antibody was detected using either PE-conjugated
F(ab)2 fragment of rabbit anti-mouse IgG (anti-IgG) or isotype-specific goat anti-mouse IgG1 (anti-IgG1 isotype specific). A total of 10,000 events
were collected for each sample. Plots display fluorescence intensity (abscissa) versus the number of events (ordinate).
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Nucleotide sequence accession number. The sequence of feline CD134L has
been lodged with GenBank, accession number DQ269941.
RESULTS
An anti-feline CD134 monoclonal antibody. The immunore-
activity of the 7D6 monoclonal antibody was examined on
feline MCC cells stably transduced with feline or human
CD134 (Fig. 1). 7D6 labeled 99.1% of feline CD134-expressing
cells (Fig. 1B; mean fluorescence intensity [MFI], 50.4) and
94.0% of human CD134-expressing cells (Fig. 1C; MFI, 64.2)
with no background on vector-only control cells (Fig. 1A;
0.4%). Anti-human CD134 (BerACT35) recognized 99.9% of
human CD134-expressing cells (Fig. 1F; MFI, 116.3) and
91.9% of feline CD134-expressing cells (Fig. 1E; MFI, 9.6), a
reduction in mean fluorescence intensity of 50-fold. It was
notable that BerACT35 also gave significant background bind-
ing on the vector-only control cells (Fig. 1D; 17.2%). Thus,
where antigen is abundant, as in transduced MCC cells, either
antibody performs well. However, the anti-feline CD134 anti-
body may perform more efficiently at low antigen levels. To
test this hypothesis, CD134 expression on IL-2-dependent
T cells (MYA-1 cells) was analyzed using either 7D6 or
BerACT35. Antibody binding was detected using the same
PE–anti-mouse IgG (whole molecule) as in Fig. 1A to F. While
7D6 recognized 60.7% of MYA-1 cells (Fig. 1G), BerACT35
failed to detect CD134 expression on the MYA-1 cells (Fig.
1H; 1.8% compared with isotype-matched control of 0.3% [not
shown]), indicating that the 7D6 antibody was more sensitive in
the detection of low levels of feline CD134 expression. Staining
of IL-2-dependent T cells, such as MYA-1 or Q201 with
BerACT35 is weak and requires amplification with a high-
affinity secondary antibody conjugate (29). Therefore, we com-
pared the detection of CD134 on MYA-1 and Q201 cells using
MAbs 7D6 and BerACT35 in conjunction with a broad-spec-
ificity conjugate (anti-IgG) or an isotype-specific conjugate
(anti-IgG1). While 7D6 detected CD134 on both cell lines
irrespective of the conjugate, BerACT35 only detected CD134
when used in conjunction with the isotype-specific anti-IgG1
conjugate (Fig. 2). The specificity of the 7D6 antibody was
confirmed further by immunoblotting against the original im-
munogen against which it was raised, soluble feline CD134-
IgG Fc fusion protein (Fig. 1I, lane 1) and against lysates of
MCC cells transduced with vector-only control (Fig. 1I, lane 2)
or with feline CD134 (Fig. 1I, lane 3). A single 43-kDa
species was recognized in the latter cells.
CD134 expression in the cat. Having confirmed the sensitiv-
ity and specificity of the 7D6 antibody, we analyzed CD134
expression on feline peripheral blood mononuclear cells to
ascertain whether CD134 expression correlated with the cellu-
lar targets for FIV. CD134 expression was measured on CD4
and CD8 T cells, B220 (CD45R) B cells and CD14
monocytes. Peripheral blood mononuclear cells were prepared
from feline blood samples that had been submitted to the
Companion Animal Diagnostics laboratory for routine virolog-
ical testing and which were feline leukemia virus, FIV, and
feline coronavirus negative, and then the cells were processed
FIG. 3. CD134 expression on feline PBMC. Lymphoid and monocytoid analysis gates (A) were set based on forward scatter (FSC) versus 90o
side scatter (SSC) and expression of CD14. CD134 expression was detected on the total population using MAb 7D6 followed by a PE–anti-mouse
conjugate, and cells were then double-stained with FITC-conjugated anti-CD4 (B), CD8 (C), or CD14 (E) or CyChrome-conjugated B220 (D).
Events were recorded in the lymphoid gate (B to D) and monocytoid gate (E). Cells were processed for flow cytometry, and 10,000 events were
collected in LIST mode. Data are representative of multiple analyses (n 	 13).
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for flow cytometry. T-cell expression of CD134 was restricted
to the CD4 (helper) subpopulation (3.8% 
 0.5% of total
cells, 12% of CD4 cells), while CD8 T cells were consis-
tently negative (0.1% 
 0.04% of total cells, 1% of CD8
cells) (Fig. 3 and Table 1). CD134 expression was also detected
on a subpopulation of B220 lymphocytes (2.0% 
 0.5% of
total cells, 5% of B220 cells) (Fig. 3). Although B220 is
expressed predominantly on feline B cells, a subpopulation of
both CD4 and CD8 T cells also express B220 (not shown).
However, only 1% of B220/CD134 cells were also positive
for CD4, suggesting that the remaining 4% of B220/CD134
cells were bona fide B cells (Table 1). CD14 monocytes in
peripheral blood were consistently CD134 negative (0.2% 

0.04% of total cells, 1% of CD14 cells) (Fig. 3). Thus, in
peripheral blood, CD134 expression is restricted to CD4 T-
cell and B220 B-cell subpopulations. The levels of CD134
expression on CD4 T cells (Table 1) are similar to those
described previously for OX40 in rats, mice, and humans
(2, 27).
Given that peripheral blood monocytes were ostensibly neg-
ative for CD134 and yet cells of the monocyte/macrophage
lineage are known to support FIV infection, we analyzed
CD134 expression on enriched splenic macrophages following
culture in the presence of GM-CSF. A 75.2% proportion of the
GM-CSF-cultured cells expressed CD14 (Fig. 4A), as expected
for cells of the macrophage lineage. A 16.1% proportion of
CD14 cells coexpressed CD134 (Fig. 4B), while 92.1% ex-
pressed CXCR4 (Fig. 4C). Following incubation for 48 h with
LPS, 31.9% of CD14 cells expressed CD134 (Fig. 4E) while
88.5% expressed CXCR4 (Fig. 4F). These data are consistent
with CD134 being up-regulated on macrophages following ac-
tivation, although expression levels remain low but comparable
to that of the IL-2-dependent T-cell line MYA-1 (Fig. 1G). We
next asked whether the increase in CD134 expression corre-
lated with enhanced infection with FIV. The splenic macro-
phages analyzed in Fig. 4A to F were infected with HIV (FIV)
luciferase pseudotypes bearing GL8, CPG41, or B2542 Envs
(Fig. 4G). LPS-stimulated macrophages showed an enhanced
susceptibility to infection with all three viruses (1.9-, 1.5-, and
2.5-fold enhancement for GL8, CPG41, and B2542, respec-
tively), consistent with the increased CD134 expression having
functional consequences.
Analysis of CD134 expression on peripheral blood mononu-
clear cells (PBMC) had indicated that expression was re-
stricted largely to CD4 T cells and B220 cells. We next
examined the expression of CD134 on cells of peripheral
lymph nodes, mesenteric lymph nodes, spleen, and thymus
collected post mortem. While CD134 expression was detected
on both CD4 T cells and B220 cells on PBMC (Fig. 5A to
C), the majority of CD134 expression in peripheral lymph
nodes (Fig. 5D to F), spleen (Fig. 5G to I), thymus (Fig. 5J to
L), and mesenteric lymph nodes (Fig. 5M to O) was restricted
to CD4 T cells. Even in the thymus, where CD4 and CD8 are
coexpressed on T-cell precursors, CD134 expression was re-
stricted to CD4 cells, indicating expression by mature (CD8-
negative) CD4 T cells only. While the majority of FIV-in-
fected cells in early infection is CD4 T cells (10, 17), in late
infection, both B cells and CD8 T cells are infected. Given
the absence of CD134 expression on CD8 T cells from either
peripheral blood or tissues, we investigated whether, as in
humans and mice, expression would be induced following mi-
togenic stimulation. Lymph node cells from two animals were
incubated in the presence of the T-cell mitogens concanavalin
FIG. 4. Macrophage expression of CD134. Splenic macrophages were cultured in the presence (D to F) or absence (A to C) of bacterial LPS
and analyzed for expression of CD14 (A and D). CD14-positive macrophages were gated and analyzed for expression of CD134 (B and E) and
CXCR4 (C and F). (G) Parallel cultures were infected with HIV (FIV) luciferase pseudotypes bearing GL8, CPG41, or B2542 Envs, and luciferase
activity was analyzed at 72 h postinfection. CON, control without infection. Data are means 
 standard errors (n 	 3).
TABLE 1. CD134 expression on lymphocytes and monocytes in
peripheral blood
Cell population % Positivea Cell population % Positivea
CD4 30.0 (3.2) B220 39.9 (3.9)
CD4 CD134 3.8 (0.5) B220 CD134 2.0 (0.5)
CD8 15.2 (1.7) B220 CD4 CD134 0.4 (0.1)
CD8 CD134 0.1 (0.04) CD14 30.4 (4.6)
CD14 CD134 0.2 (0.04)
a Mean percent positive (standard error) (n 	 13).
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FIG. 5. CD134 expression on cells from peripheral blood (A to C), popliteal lymph node (D to F), spleen (G to I), thymus (J to L), and
mesenteric lymph node (M to O). Cell suspensions were stained indirectly with anti-CD134 followed by PE–anti-mouse followed by double-staining
with CD4-FITC and CD8-FITC or CyChrome-B220. Cells were processed for flow cytometry, and 10,000 events were collected in LIST mode.
Data are representative of multiple analyses (n 	 12).
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A (ConA) and phytohemagglutinin (PHA) for 1 week and
analyzed by flow cytometry for CD134 expression (Fig. 6) on
CD4 and CD8 T cells and B220 cells. Following ConA
stimulation, CD134 expression on CD4 T cells increased
from 1.9% and 2.3% on day 1 to 10.5% and 19.4% on day 7.
PHA stimulation had an even more striking effect, increasing
CD134 expression on CD4 T cells to 14.1% and 35.9%. Thus,
CD134 expression is increased by mitogenic stimulation of
CD4 T cells. ConA stimulation increased CD134 expression
marginally on CD8 T cells (from 0.5% and 0.3% on day 1 to
0.8% and 1.0% on day 7). PHA stimulation increased CD134
expression on CD8 T cells to 1.0% and 2.4% by day 7 post-
exposure, confirming a modest but detectable increase of
CD134 expression in postmitotic CD8 T cells. A modest
increase in CD134 expression was also observed on B220 T
cells. However, the majority B220 CD134 cells in these
cultures coexpressed CD4 or CD8 (Fig. 6, tomogram plots),
consistent with ConA and PHA acting as T-cell (and not B-
cell) mitogens.
Anti-CD134 inhibition of FIV infection. HIV (FIV) lucifer-
ase pseudotypes bearing Envs from GL8, B2542, CPG41, and
0827 were used to infect MCC cells stably expressing fCD134
(MCC-fCD134) (Fig. 1B) in the presence of increasing con-
centrations of the 7D6 anti-CD134 antibody (Fig. 7). The abil-
ity of 7D6 to block viral entry was reproducible but Env de-
pendent. GL8 and CPG41 were the least sensitive to the
inhibitory effects of 7D6; infection with both viruses was re-
duced by 65% at 4 g/ml 7D6. In contrast, infections with
B2542 and 0827 were reduced by 88% and 83%, respectively.
It is noteworthy that with increasing antibody concentration
the inhibitory effect was either reduced (B2542 and 0827) or
was no longer significant (GL8 and CPG41). Infection medi-
ated by the G protein of vesicular stomatitis virus (VSV-G) was
not affected by 7D6 (not shown). If there were a direct com-
petition between 7D6 and Env for CD134 binding, one might
expect infection to be ablated completely in a dose-dependent
manner. Thus, these data may indicate an indirect or allosteric
effect.
The binding site for CD134L on CD134 utilizes residues
from the first, second, and third cysteine-rich domains (CRD1,
CRD2, and CRD3) (7), while residues in CRD2 are critical in
determining the species specificity of the human CD134L-
CD134 interaction (38). The binding site for soluble FIV
SU-Fc on CD134 has been mapped to CRD1 (11), while ad-
ditional determinants in CRD2 have been shown to contribute
to infection mediated by viruses such as FIV GL8 (38, 39).
Previous studies have demonstrated that the herpes simplex
virus glycoprotein D (HSV-gD) and LIGHT (lymphotoxin-
like, exhibits inducible expression and competes with HSV
glycoprotein D for HveA and is expressed on T lymphocytes)
bind distinct sites on the herpes simplex virus entry mediator A
(HveA) and yet cross-compete for binding (28) (indicating an
allosteric effect). Given that 7D6 inhibited infection with FIV
Env-bearing pseudotypes, we asked whether 7D6 would block
binding of soluble FIV SU-Fc fusion protein to MCC-fCD134.
Preincubation of MCC-fCD134 with 7D6 reduced binding of
either FIV GL8 SU-Fc (Fig. 7C) or PPR SU-Fc (Fig. 7F) at 1
g/ml and more substantially at 10 g/ml, indicating that the
antibody did indeed disrupt binding of FIV SU. Mean fluores-
cence intensity of GL8 SU-Fc binding was reduced from 69.3
to 29.8 (Fig. 7I), while that of PPR SU-Fc was reduced from
101.3 to 25.4 (Fig. 7J). Although SU-Fc binding was reduced
reproducibly, it was never abolished completely, suggesting the
7D6 antibody may target a specific high-affinity binding and
that there is a substantial 7D6-resistant binding component
(e.g., CXCR4 or heparin sulfate-dependent binding [12, 15]).
Binding of either FIV GL8 SU-Fc (Fig. 7E) or PPR SU-Fc
(Fig. 7H) was unaffected by incubation with isotype-matched
anti-CD8 (VPG9). Given that MAb BerACT35 had a weaker
reactivity with feline CD134 than human CD134 (Fig. 1), we
asked whether BerACT35 would also interfere with SU-Fc
binding to MCC-fCD134. BerACT35 had no effect on GL8
SU-Fc (Fig. 7D), while with PPR SU-Fc (Fig. 7G) there was a
modest enhancement of SU-Fc binding. The significance of
this increase in binding was not ascertained but may reflect the
BerACT35 antibody altering the configuration of CD134 such
that the PPR-SU Fc binding site is more readily accessible.
Effect of CD134L on FIV infection. The binding site for
soluble FIV PPR SU-Fc fusion maps to CRD1 of CD134 (11),
and expression of CRD1 of feline CD134 alone in the context
of human CD134 is sufficient to facilitate binding and infection
with FIV PPR. In contrast, other strains of FIV require deter-
minants in CRD2 for infection to proceed (39), determinants
that map to the alternate face of CD134 and which contribute
to the binding site for CD134L (38). Infection with viruses such
as GL8 is critically dependent on these determinants in CRD2,
raising the possibility that infection may be susceptible to mod-
ulation (inhibition or enhancement) by the engagement of
CD134 by CD134L. To investigate the role of CD134L in FIV
infection, we cloned feline CD134L from MYA-1 cells and
confirmed its ability to bind fCD134. Soluble fCD134-Fc fusion
protein bound specifically (Fig. 8A, 92.7%) to MCC cells stably
transduced with fCD134L, compared with vector-only trans-
duced control cells. fCD134L bound fCD134-Fc selectively
(Fig. 8B), and binding was dependent on determinants in
CRD2 in that soluble chimeric fCRD1 in the context of human
CD134 (Fig. 8B, fCRD1/h) fusion protein did not bind to
MCC-fCD134L cells. Binding of the fCRD1/h fusion protein
could be restored partially by mutation of residues 78SSK80 of
the human CD134 CRD2 in the fCRD1/h fusion protein to
78NYE80 (Fig. 8B, fCRD1/hNYE). Thus, the feline CD134L
was expressed in a biologically relevant configuration that sup-
ported feline CD134 binding specifically. We next asked
whether a biologically active soluble fCD134L could be gener-
FIG. 6. Effect of T-cell mitogens on CD134 expression. Lymph node cells from two animals (upper and lower panels, respectively) were
cultured with the T-cell mitogens ConA and PHA for 7 days. Cells were then stained indirectly with anti-CD134 followed by PE–anti-mouse
followed by double staining with CD4-FITC and CD8-FITC or CyChrome-B220. Cells were processed for flow cytometry, and 10,000 events
were collected in LIST mode. Data were analyzed using Expo32 v1.2. Tomograms represent three-color staining of PHA day 7 cells, and an
indicative CD4 CD134 B220 population is circled.
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ated from the cDNA clone. Soluble feline, murine, and human
CD134Ls were expressed as Fc fusion proteins and adjusted to
equivalent concentrations, and their binding properties were
examined. While there was no specific binding of the proteins
to control MCC cells (Fig. 8C), murine Fc-CD134L bound to
MCC cells expressing either feline (Fig. 8D) or human (Fig.
8E) CD134, consistent with the promiscuous binding of this
ligand (5). Human Fc-CD134L bound specifically to human
CD134-expressing cells (Fig. 8E) and not feline CD134-ex-
pressing cells, in agreement with the species specificity of this
ligand (5, 11, 38). In contrast, feline CD134L binding to either
cell line could not be detected. Similar results were obtained
when the soluble CD134Ls were prepared as FLAG-tagged
fusion proteins (not shown). The data suggest that feline
CD134L does not retain its specific binding properties when
expressed in a soluble form, perhaps due to inappropriate
aggregation (loss of ligand activity for related molecules
[mFasL and mLIGHT] following expression as Fc-fusion pro-
teins has been observed previously [5]). However, given that
murine CD134L bound feline CD134 well (Fig. 8D), we were
able to proceed with experiments to examine the effect of
CD134L engagement on FIV infection using murine CD134L
as a surrogate ligand.
We investigated the nature of the 7D6 binding site on
fCD134. Firstly, we examined the effect of 7D6 on binding of
soluble feline CD134-Fc to MCC cells stably transduced with a
feline CD134L expression vector. sfCD134-Fc bound well to
MCC-fCD134L cells (97%) (Fig. 8F); however, preincubation
of sfCD134-Fc with 1 g/ml 7D6 reduced binding to 7.0% (Fig.
8F), while binding was blocked completely by preincubation
with 10 g/ml 7D6 (0.2%) (Fig. 8F). Thus, 7D6 competes with
fCD134-Fc for binding to fCD134L. In the converse experi-
FIG. 7. Inhibition of FIV infection by anti-CD134 MAb 7D6. MCC cells expressing feline CD134 were preincubated with 7D6 and then exposed
to HIV (FIV) pseudotypes bearing GL8 or B2542 (A) and CPG41 or 0827 (B) Envs. Cells were cultured for 72 h postinfection, and luciferase
activity was quantified. Data are means
 standard errors (n	 3) and are representative of three experiments. MAb 7D6 reduces binding of SU-Fc
fusion proteins. MCC cells expressing feline CD134 were preincubated with 0.1, 1.0, or 10 g/ml MAb 7D6 (C and D), BerACT35 (D and G), or
isotype-matched control anti-CD8, VPG9 (E and H), prior to addition of GL8 SU-Fc (C to I) or PPR SU-Fc (F to J). (I and J) Effects of MAbs
on mean fluorescence intensity for GL8 SU-Fc (I) and PPR SU-Fc (J). Bound SU-Fcs were detected with PE-conjugated anti-human IgG-Fc. The
arrow indicates the reduction in fluorescence intensity. Data are representative of three experiments.
9674 WILLETT ET AL. J. VIROL.
 at BIBLIO
THEQUE DU CHUV on July 15, 2008 
jvi.asm.org
D
ow
nloaded from
 
ment, we looked at the ability of 7D6 to block binding of
soluble Fc-mCD134L to MCC-fCD134 cells. Human and mu-
rine CD134Ls were transiently expressed as Fc fusion proteins
in 293T cells. We then examined the effect of 7D6 on the
binding of soluble Fc-mCD134L to MCC-fCD134. 7D6
blocked binding of Fc-mCD134L to MCC-fCD134 at 10 g/ml
(Fig. 8G), indicating that the antibody interferes with the site
of interaction between CD134 and CD134L either directly or
FIG. 8. Interaction between CD134 and CD134L. (A) MCC cells stably transduced with feline CD134L (open histogram) or vector-only control
cells (filled histogram) were incubated with 1 g soluble feline CD134-Fc fusion protein followed by PE–anti-human IgG-Fc. (B) CRD1-dependent
binding of CD134 to feline CD134L-expressing MCC cells. Cells were incubated with feline CD134-Fc (fCD134), a human CD134 CRD1  feline
CD134 chimera (fCRD1/h), or fCRD1/h with 78SSK90 mutated to 78NYE90. (C to E) Binding of soluble feline, human, or murine Fc-CD134L to
vector-only control MCC (C) or MCC expressing feline CD134 (D) and human CD134 (E). Bound ligand was detected with PE–anti-human
IgG-Fc. (F) Inhibition of soluble feline CD134-Fc to MCC-fCD134L cells by anti-CD134 MAb 7D6. Cells were preincubated with 0, 1, or 10 g/ml
7D6 prior to incubation with 1 g feline CD134-Fc. The arrow indicates a reduction in fluorescence intensity. (G and H) Effects of MAb 7D6 on
murine Fc-CD134L binding to MCC cells expressing feline (G) or human (H) CD134. Cells were preincubated with 0.1, 1, or 10 g/ml of MAb
7D6 followed by 50 l (1 g) soluble murine Fc-CD134L. The arrow indicates a reduction in fluorescence intensity. All bound ligands were
detected with PE–anti-human IgG-Fc, while filled histograms represent binding of PE–anti-human IgG-Fc in the absence of ligand. Data are
representative of three experiments.
VOL. 81, 2007 CD134-CD134L INTERACTION IN FIV INFECTION 9675
 at BIBLIO
THEQUE DU CHUV on July 15, 2008 
jvi.asm.org
D
ow
nloaded from
 
through an allosteric affect. In contrast, 7D6 did not inhibit
binding of Fc-mCD134L to MCC-hCD134 at 10 g/ml (Fig.
8H), consistent with the antibody recognizing human CD134
with a reduced affinity compared to feline CD134 (Fig. 1).
The blocking of HSV infection by LIGHT (22) and the
cross-competition between HSV gD and LIGHT for binding to
HveA (28) indicate that even if the Env and CD134L binding
sites on CD134 are noncontiguous, viral entry may be blocked
by ligand engagement through an allosteric mechanism. We
therefore examined the effect of soluble CD134L on FIV infec-
tion. MYA-1 cells were incubated sequentially with mCD134L
followed by HIV (FIV) pseudotypes. Preincubation of feline T
cells with soluble mCD134L blocked infection with B2542 and
PPR in a dose-dependent manner (Fig. 9A). In contrast,
CPG41 and GL8 were relatively resistant to the blocking effect
of mCD134L, while 0827 and 1419 displayed a marginal en-
hancement of infection at the highest concentration, indicating
that there may be strain-specific differences in sensitivity to
antagonism by CD134L and that, depending on the strain of
virus, the ligand may either inhibit or even facilitate infection.
We repeated the assay for inhibition of viral entry using a
single fixed dose of mCD134L (10 g/ml) with the modification
that following the incubation with HIV (FIV) pseudotypes for
2 h, unbound pseudotypes were removed by centrifugation and
FIG. 9. Effect of soluble murine Fc-CD134L on FIV infection. (A) MYA-1 cells were preincubated with soluble Fc-mCD134L followed by HIV
(FIV) luciferase pseudotypes bearing GL8, B2542, 0827, CPG41, PPR, or 1419 Envs. Cells were cultured for 72 h, and luciferase activity was
quantified. (B) MYA-1 cells were preincubated with 10 g/ml soluble Fc-mCD134L followed by HIV (FIV) luciferase pseudotypes bearing GL8,
B2542, 0827, CPG41, PPR, NCSU, 0425, or 1419 Envs. At 2 h postinfection, cells were washed and plated. Cells were cultured for 72 h, and
luciferase activity was quantified. All data are means 
 standard errors (n 	 3) and are representative of three experiments. (C) Graphical
representation of the dependence of a viral strain on CRD2 of CD134 for infection (39) (CRD2 usage is the luciferase activity in fCD134-
expressing MCC cells divided by luciferase activity in MCC cells expressing fCRD1 alone) and sensitivity to mCD134L (percent reduction in
infection at 10 g/ml Fc-mCD134L).
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cells were reseeded in medium supplemented with mCD134L
(Fig. 8B). Again, using the modified “washout” protocol, the
most marked effect was observed with B2542 and PPR (82%
and 90% reductions in viral entry, respectively). Under these
conditions, mCD134L also reduced infection with 0827, 0425,
1419, and CPG41 Env-bearing pseudotypes to some extent (20
to 50%), but NCSU was entirely resistant to inhibition by the
mCD134L at 10 g/ml. We next examined a possible correla-
tion between sensitivity to inhibition by CD134L and the in-
teraction pattern of the different viral strains on CD134. In-
deed, we have shown previously that some strains require only
determinants in CRD1 for infection (e.g., PPR) whereas others
also make use of CDR2 determinants, in particular the se-
quence 78NYE90 (e.g., GL8) (38, 39). As shown in Fig. 9C,
there was an inverse correlation between CD134L sensitivity
and CRD2 usage, such that viruses with a greater dependence
on CRD2 were least sensitive to inhibition by mCD134L and
vice versa. This is in line with our previous hypothesis that an
extended and complex interaction of the virus with CD134 is of
higher affinity(38, 39) and, therefore, more difficult to displace
with CD134L. The dependence on CRD2 for infection may
thus represent a surrogate measure of receptor affinity and of
the ability to displace CD134L.
DISCUSSION
FIV is the only nonprimate lentivirus that in its natural host
species, the domestic cat, induces a disease similar to AIDS
(26). Acute infection with FIV is accompanied by a selective
targeting of CD4 T lymphocytes, resulting in a progressive
decline in CD4 T helper cell number (1). In chronic infection,
an immunodeficiency syndrome develops that is characterized
by wasting, neurological manifestations, chronic stomatitis and
gingivitis, and an increased incidence of lymphoma (25). In
contrast, the ungulate lentiviruses induce diseases reminiscent
of chronic inflammatory conditions. The progression from the
acute to the chronic phase of infection is accompanied by an
expansion of the viral cell tropism, perhaps indicative of a shift
in the receptor usage analogous to the emergence of CXCR4-
using variants in HIV infection with disease progression (8).
The early targeting of FIV to CD4 helper T cells would be
explained if CD134 expression in the domestic cat were re-
stricted to this cell population, as has been observed in the rat
(24). Human CD134 expression is also restricted predomi-
nantly to CD4 T cells, although expression has been noted on
CD8 T cells following stimulation with allogeneic monocyte-
derived dendritic cells (18) and more rarely on B-cell blasts
(16). In comparison, murine CD134 is expressed not only on
CD4 T cells but also in substantial amounts on mitogen-
stimulated CD8 T cells (2). Using the 7D6 anti-feline CD134
monoclonal antibody, we have now shown that CD134 expres-
sion in the domestic cat is restricted largely to CD4 T cells,
not only in peripheral blood but also in spleen, thymus, and
lymph nodes. Indeed, the degree of restriction of CD134 ex-
pression to CD4 T cells is striking, suggesting tight regulation
of gene expression. On thymocytes, CD134 expression re-
mained restricted to CD4 T cells, suggesting that CD4
CD8 thymocytes are CD134 negative and that CD134 is only
expressed on mature CD4 T cells. Thus, the restriction of
feline CD134 expression to CD4 T cells mirrors the reported
expression pattern in the rat.
CD134 expression was induced, albeit weakly, on CD8 T
cells in vitro following exposure to the T-cell mitogens ConA
and PHA. These findings are similar to observations with
mouse and human T cells, where CD134 expression is abun-
dant on activated CD4 T cells but is low on activated CD8
T cells (2, 18). In contrast, CD8 rat T cells are CD134 neg-
ative (2), although expression was detected on a CD4 CD8
population (2). In this study, we used double staining with
CD134 and CD8 to confirm the cellular lineage. Whether
CD134 expression is induced in vivo under conditions of im-
mune activation remains to be established. However, these
data would explain how FIV can also infect CD8 T cells in
chronically infected animals. In early infection, the virus would
target the cell population upon which expression of CD134 is
most abundant, activated CD4 T cells. As the infection
progresses, the virus may then expand into less-abundant
CD134-positive populations, such as CD8 T cells.
CD134 expression was observed on a peripheral B220 pop-
ulation, the majority of which were CD4 and CD8 negative,
consistent with the B-cell lineage (these cells were distinguish-
able from the B220 populations of mitogen-stimulated CD4
and CD8 T cells generated in vitro, which coexpressed
CD134). B220/CD45R is a marker used widely for the B-cell
lineage; it is expressed on B cells at all stages of development
but is reduced on plasma cells and a memory B-cell subset. B
cells are known to be a significant reservoir of FIV proviral
DNA in peripheral blood in chronic infection (10, 17), and the
expression of CD134 would be consistent with these cells being
targeted. B220 is also expressed on NK1.1 CD8 TCR
B220 lymphokine-activated killer cells (3); however, the
CD134 B220 cells in feline peripheral blood in this study
reacted with neither anti-CD8 nor anti-CD57 (NK1.1), fur-
ther supporting the B-cell lineage of the cells. A third popu-
lation of CD134-positive cells in the “lymphoid” gate in pe-
ripheral blood were CD4, CD8, CD8, and B220 negative.
The lineage of this population in the domestic cat remains to
be determined, and identification remains problematic due to
the paucity of reagents recognizing feline leukocytes. However,
it is possible that this population may include either NK cells or
a B220-negative (memory) subset of B cells.
The levels of CD134 detected on PBMC populations in this
study are consistent with those reported for murine or human
PBMC; however, they are significantly lower than those in-
ferred by binding studies using soluble FIV Env SU-Fc pro-
teins, where SU-Fc bound to approximately 60% of PBMC
(12), the majority of which (77%) was ablated by the CXCR4
antagonist CXCR4 (12). Given that CXCR4 expression on
freshly isolated feline PBMC is restricted to B cells and mono-
cytes (36), the data suggest that SU-Fc binding is an unreliable
measure of CD134 expression. It is likely that this reflects the
monomeric/dimeric structure of the SU-Fc protein where the
CXCR4 binding site may be more readily exposed. Indeed,
although we found that MAb 7D6 reduced binding of GL8
SU-Fc significantly, there was a high degree of binding that was
refractory to 7D6 and found subsequently to be CD134 inde-
pendent (not shown). Given that the GL8 strain is highly
CD134 dependent, the high degree of nonspecific binding as-
sociated with the GL8 SU-Fc suggested to us that this ap-
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proach was not representative of the virus-receptor interaction
and was not pursued further.
Diverse strains of FIV target cells of the monocyte/macro-
phage lineage (9, 32, 33), indicating that the cellular recep-
tor(s) for FIV may be expressed in cells of this lineage. Flow
cytometric analyses of CD134 expression on PBMC indicated
that CD14 cells (monocytes) were ostensibly negative. We
therefore postulated that CD134 may be expressed on macro-
phages and that expression may be enhanced by activation.
CD134 expression was indeed detected on cultured macro-
phages, expression was up-regulated following exposure to
bacterial LPS, and the enhanced expression correlated with an
increase in susceptibility to infection. Thus, while HIV targets
monocytes/macrophages via expression of CD4, FIV achieves a
similar targeting by using CD134 (CD4 is not expressed on
feline monocytes/macrophages). The restricted expression of
CD134 to macrophages (and not monocytes) would indicate
that targeting of this lineage FIV most likely occurs in immu-
nological tissues, at sites where helper T cells and antigen-
presenting cells are brought into close proximity. Previous
studies have demonstrated that FIV interacts with DC-SIGN
(14), providing a useful means of delivering the virus to areas
of lymphoid tissues that are rich in the target cells for the virus.
It would appear then that the use of CD4 and CD134 by HIV
and FIV may be a means to an end, the viruses acquiring the
use of a primary receptor to enhance their ability to replicate
in helper T cells and macrophages.
The interaction between the TNF superfamily and TNFR
superfamily molecules TRAILR(DR5)-TRAIL(Apo2L) and
TNFR-LT/TNF is mediated by residues in CRD2 and CRD3
of the TNFR superfamily molecule and the ligand (reviewed in
reference 4), leading to speculation that the interaction be-
tween FIV and CD134 is not modulated by engagement of
CD134 by CD134L (11). Accordingly, human CD134L bound
to a chimera expressing feline CD134 CRD1 in the context of
human CD134, and infection via this chimeric receptor with
FIV pseudotypes bearing the FIV PPR Env was not blocked by
human CD134L. However, subsequent studies demonstrated
that diverse strains of FIV require determinants in CRD2 of
CD134 for infection, indicating that infection with these vi-
ruses may be susceptible modulation by CD134L. Moreover,
the crystal structure of the complex between human CD134
and either human or murine CD134L has revealed that resi-
dues in not only CRD2 and CRD3 but also CRD1 contribute
to the receptor-ligand interaction (7).
In order to probe the FIV-CD134 interaction, we cloned
fCD134L. Surface-expressed fCD134L bound feline but not
human CD134, and this interaction was dependent on CRD2.
MAb 7D6 blocked this interaction efficiently. However,
fCD134L did not retain biological activity when prepared in
soluble forms, impeding studies of antagonism of the FIV-
CD134 interaction. However, given that mCD134L binds not
only to human but also murine CD134 (5), we postulated that
this promiscuity could extend to feline CD134. Indeed,
mCD134L bound feline CD134, and this interaction was in-
hibited by MAb 7D6. We were then able to utilize mCD134L
to probe the FIV-CD134 interaction and showed that
mCD134L blocked FIV infection in an apparently strain-spe-
cific and dose-dependent manner. Critically, the two viral
strains that were most sensitive to the inhibitory effects of
mCD134L (PPR and B2542) were also sensitive to inhibition
by MAb 7D6 and able to utilize chimeras expressing CRD1 of
feline CD134 alone efficiently (38, 39). Conversely, strains such
as GL8 and CPG41 show a strict dependence on CRD2 of
CD134 and are less sensitive to inhibition by either MAb 7D6
or mCD134L. While the concordance between dependence on
CRD2 for infection and refractoriness to inhibition by MAb
7D6 or mCD134L is compelling, it is likely that additional
factors will contribute to the efficiency of viral entry in vivo, for
example, affinity for CXCR4. Indeed, NCSU shows high de-
pendence on CRD2 on feline (MCC) cells but low dependence
on human (HeLa) cells (39); HeLa cells express high levels of
human CXCR4, which is, paradoxically, a more efficient core-
ceptor for FIV than feline CXCR4 (34). Accordingly, infection
with NCSU has been reported to correlate primarily with level
of CXCR4 expression (21). These data may implicate a model
for infection where the viruses that are transmitted and which
are present in early infection (asymptomatic phase in HIV
infection), such as CPG and GL8, may interact with CD134
with a higher affinity and thus may target cells more efficiently
where CD134 levels are limiting. As a result of their strict
dependence on a complex (and high-affinity) interaction with
CD134, these viruses may be less sensitive to neutralizing an-
tibodies targeting the CXCR4 binding site. With disease pro-
gression (late infection, the symptomatic phase in HIV infec-
tion), viruses such as B2542 and PPR may be more prevalent.
These viruses require only a minimal interaction with CD134
before interacting with CXCR4, the CXCR4 binding site being
readily exposed, and may be more sensitive to both CD134L
and neutralizing antibodies. Accordingly, infection with the
PPR strain can be facilitated by simply overexpressing CXCR4
(13), while CXCR4 overexpression has a minimal effect on
viruses such as GL8 (35). Thus, with disease progression, vi-
ruses may evolve towards CD134 independence, the cell tro-
pism mirroring the broad cellular distribution of CXCR4,
while in early infection the viral cell tropism may reflect the
limited distribution of CD134.
The binding of FIV Env, MAb 7D6, and CD134L to CD134
would appear to be inextricably linked, analogous to the bind-
ing of HSV gD, LIGHT, and LT- to HveA (28). Given that
engagement of CD134 by CD134L promotes the survival of
antigen-specific T cells, future studies should address whether
the FIV Env, either oligomeric on the viral particle or in a
soluble form, shed into the extracellular milieu, antagonizes
this survival signal or mimics it, promoting the expansion of a
population of CD4 helper T cells that provide the ideal home
for an AIDS-causing lentivirus.
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